ScholarLens Back to search
2009•Expert Opinion on Drug Metabolism & ToxicologyRequires access

Evaluation of combination long-acting β-2 agonists and inhaled glucocorticosteroids for treatment of asthma

Dennis Kim, Mark C. Glaum, Richard Lockey

Open publisher page 4 citations

Abstract

BACKGROUND: Treating asthma with a combination of inhaled corticosteroid and a long-acting beta-2-agonist is often preferred when asthma is not controlled when using a low-medium dose of an inhaled corticosteroid. OBJECTIVE: To review the pharmacology, efficacy and safety of inhalers containing combinations of long-acting bronchodilators and inhaled corticosteroids to treat moderate-to-severe, persistent asthma. METHODS: Using a list of keywords, we conducted a PubMed search of the literature. Data provided by the manufacturer were also reviewed. RESULTS: Fluticasone propionate with salmeterol and budesonide with formoterol are both well tolerated, have equal clinical efficacy and have recent data affirming their safe use in diverse patient populations. CONCLUSIONS: Combination inhalers improve asthma control in patients previously uncontrolled on inhaled corticosteroids.

About this research paper

What this paper is about

BACKGROUND: Treating asthma with a combination of inhaled corticosteroid and a long-acting beta-2-agonist is often preferred when asthma is not controlled when using a low-medium dose of an inhaled corticosteroid. OBJECTIVE: To review the pharmacology, efficacy and safety of inhalers containing combinations of long-acting bronchodilators and inhaled corticosteroids to treat moderate-to-severe, persistent asthma. METHODS: Using a list of keywords, we conducted a PubMed search of the literature. Data provided by the manufacturer were also reviewed. RESULTS: Fluticasone propionate with salmeterol and budesonide with formoterol are both well tolerated, have equal clinical efficacy and have recent data affirming their safe use in diverse patient populations. CONCLUSIONS: Combination inhalers improve asthma control in patients previously uncontrolled on inhaled corticosteroids.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND: Treating asthma with a combination of inhaled corticosteroid and a long-acting beta-2-agonist is often preferred when asthma is not controlled when using a low-medium dose of an inhaled corticosteroid. OBJECTIVE: To review the pharmacology, efficacy and safety of inhalers containing combinations of long-acting bronchodilators and inhaled corticosteroids to treat moderate-to-severe, persistent asthma. METHODS: Using a list of keywords, we conducted a PubMed search of the literature. Data provided by the manufacturer were also reviewed. RESULTS: Fluticasone propionate with salmeterol and budesonide with formoterol are both well tolerated, have equal clinical efficacy and have recent data affirming their safe use in diverse patient populations. CONCLUSIONS: Combination inhalers improve asthma control in patients previously uncontrolled on inhaled corticosteroids.

Key concepts: Fluticasone propionate, Medicine, Formoterol, Salmeterol, Budesonide, Asthma, Corticosteroid, Inhalation

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Evaluation of combination long-acting β-2 agonists and inhaled glucocorticosteroids for treatment of asthma — Research Paper | ScholarLens